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Abstract: Clinical results with oncolytic adenoviruses (OAds) used as antitumor monotherapies
show limited efficacy. To increase OAd potency, transgenes have been inserted into their genome,
a strategy known as “arming OAds”. Here, we review different parameters that affect the outcome
of armed OAds. Recombinant adenovirus used in gene therapy and vaccination have been the
basis for the design of armed OAds. Hence, early region 1 (E1) and early region 3 (E3) have been
the most commonly used transgene insertion sites, along with partially or complete E3 deletions.
Besides transgene location and orientation, transcriptional control elements, transgene function,
either virocentric or immunocentric, and even the codons encoding it, greatly impact on transgene
levels and virus fitness.
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1. Introduction
In the 1950s–1970s, anecdotal reports of spontaneous tumor remissions as a result of naturally
acquired viral infections prompted the clinical concept of using pathogenic viruses to cure cancer,
known as virotherapy. One of the first clinical trials was done in 1956 using wild-type adenovirus (Ads)
as a therapeutic agent in cervical cancer. It was demonstrated to be safe with mild flu-like symptoms
as the main adverse effects [1], and apparent efficacy with marked tumor necrosis or liquefaction of
tumors. However, the antitumor responses lasted only months and did not translate into an overall
survival benefit, unlike the promising chemotherapeutic agents, at that time.
In 1996 Frank MacCormick proposed the use of a mutant adenovirus to treat p53-deficient
tumors [2]. In the following years this virus, renamed as ONYX-015, was tested in numerous clinical
trials with limited efficacy. A similar virus was developed in China under the name Oncorine. In 2005,
it gained approval for the treatment of head and neck tumors by intratumoral injection in combination
with systemic chemotherapy [3]. The response rate with the combination doubled that obtained with
chemotherapy alone, but no overall survival improvements were reported.
To increase the efficacy of oncolytic adenoviruses major research efforts have been directed to
enhance tumor-targeting by capsid modifications, and tumor-selective replication using promoters and
gene deletions. These aspects have been broadly reviewed in the literature [4–6]. Replication-selective
oncolytic adenoviruses (OAds) with these modifications, such as CV706, CG7870, AdD24RGD,
and ICOVIR5, entered clinical trials. However, despite occasional striking tumor responses, clinical
efficacy remained low [7–11]. Thus, the potency of oncolytic adenoviruses should be further increased
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to become a real and viable cancer therapy. The insertions of transgenes into their genome, also known
as “arming OAds” [12], aims to the destruction of neighboring and distant uninfected cancer cells by
the direct or indirect effect of the transgene-encoded therapeutic proteins or RNA.
Adenovirus has several advantages compared to other oncolytic viruses for transgene insertion.
All RNA viruses except orthomyxoviruses (e.g., influenza virus) and retroviruses replicate in the
cytoplasm and therefore nuclear transcriptional control elements, such as tumor selective promoters,
are non-functional. In contrast, DNA viruses except poxviruses (e.g., vaccinia virus) replicate in the
nucleus and are compatible with the use of eukaryotic promoters. Viruses with small compact genomes
cannot accept transgenes (picornavirus, reovirus, and parvovirus). Besides, adenovirus stands out from
the rest of transgene-carrying viruses (Vesicular Stomatitis Virus, Measles Virus, Newcastle disease
Virus, Herpes Virus, and Vaccinia Virus) because it has a highly regulated temporal sequence of viral
gene expression starting with E1a which allows tuning transgene expression.
Here we review the different strategies used to arm oncolytic adenoviruses. Although the nature
of the therapeutic transgene would be the first important feature for an armed-OAd, it is crucial to
note that the amount, and timing of transgene expression are pivotal for this arming strategy. In this
review, we explore how transgene location, different transcriptional control elements, the transgene
codon usage, and the transgene itself affect its expression, kinetics, and viral replication.
2. Transgene Location Affects Expression Levels and Fitness of Armed OAds
Adenoviridae is a family of icosahedral, non-enveloped viruses with an approximately 30–40 kb
linear double-stranded DNA genome. In humans, more than 50 different serotypes associated in
six groups (A to F) have been discovered. Nevertheless, the most common for oncolytic therapy
are serotypes Ad2 and Ad5 from group C. These are the best characterized among all the serotypes;
replicate to higher yields than most other human Ad serotypes, and DNA sequences and tools are
readily available for their genetic modification [13].
Adenoviruses maximize their genome coding capacity by generating early and late transcription
units (active before or after virus DNA replication, respectively) controlled by multiple promoters, which
in turn generate different RNAs and proteins by alternative splicing [14,15] (Figure 1). The strategy to
insert additional genes stems from the use of adenoviruses as gene transfer vectors in the fields of
gene therapy and vaccination. The transcription units Early 1 (E1), E3, and E4 were used as insertion
sites for exogenous DNA sequences in the generation of recombinant Ads [16–19]. E1 is needed for
viral replication and its defect is complemented by E1-expressing vector-packaging cell lines, such as
HEK 293. In contrast, E3 mostly encodes immune-inhibitory proteins non-essential for viral replication
in vitro [16,20,21]. An advantage of using the E3 region to insert the transgene is that it provides
genomic space. Recombinant adenoviruses will only stably accommodate approximately 2 kb of
additional DNA beyond the size of the normal genome [22]. Thus, deletions are needed to encode
transgenes larger than 2kb and E1 and E3 deleted adenoviruses were used in the gene therapy field as
a backbone for large transgene insertions.
In contrast to gene therapy vectors, OAds replicate in cancer cells. Thus E1 cannot be deleted
entirely. The partial deletion of E1b55K was the first deletion postulated to be dispensable in tumor
cells, based on the rationale that the p53-blocking function of this protein is not needed in p53-deficient
cells [2]. Freytag et al. described the first armed-OAd with an E1b55K deletion and a transgene cassette
with a cytomegalovirus promoter (CMVp) controlling a cytosine deaminase gene (CD) fused to the
herpes virus thymidine kinase (TK) (Figure 1). This virus exhibited tumor cell specificity and enhanced
viral therapy thanks to transgenes [23,24]. Similarly, the thymidine kinase (TK) gene was inserted in an
E1b55K and E3-deleted adenovirus after the E1 region [25]. Since then, entire or partial E3 deletions
have been used to generate genomic space to insert expression cassettes formed by an exogenous
promoter, the transgene and polyadenylation sequences in different locations such as E1, E3 or E4
(Figure 1).
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Figure 1. Schematic representation of adenovirus geno e. Light grey represents early transcripts
(E1A, E1B, E2A, E2B, E3 and E4) and dark grey the late transcripts (L1, L2, L3, L4 and L5) produced
by alternative splicing under the ajor late pro oter ( LP). Published insertion sites and replaced
adenoviral genes are reported according to the legend.
To bypass the ne d of exogenous promoters in OAds the group led by Terry Hermiston at Onyx
substituted E3 genes with transgenes maintaining the nd genous prom ters and polyadenylati n
sites, and end wing the transgene with the expression ki etics of the substituted E3 ge e [26–28]. They
replaced the E3 6.7K and gp19K open reading frames (ORFs, Figure 1) with cytosine deaminase (CD) or
tumor necrosis factor alpha (TNFα) resulting in high levels of transgene expression and viral replication
dependency [26]. However, as gp19K is responsible for the retention of MHC-I inside the cell, these
viruses are more susceptible to be eliminated by cytotoxic T-lymphocytes (CTLs). They also substituted
the E3 gp11.6K adenovirus death protein (ADP) for CD or TNFα. As ADP is involved in the release of
viral progeny, these viruses presented a delayed cytopathic effect that could be useful for an extended
transgene production period, where the infected cell operates as a “factory” [27]. In contrast to this
lytic delay to enhance transgene production, Rohmer et al. proposed the opposite strategy combining
accelerated tumor cells lysis and transgene expression. The deletion of the anti-apoptotic E1b19K gene
substantially increases the adenoviral cell killing [29,30]. The enhancement of apoptosis-dependent
early viral release correlated with an increased transgene expression [31]. Hence, other Ad5 mutants
with early viral release/enhanced spread phenotype in tumors could be considered to increase the
transgene expression [32–34].
The Hermiston group also published the replacement of E3B adenoviral genes (RIDα/β and
14.7K, Figure 1) with TNFα. They obtained the highest levels of transgene compared with the other
two insertion sites (6.7K/19K or ADP). This site conferred late gene kinetics and did not interfere
with viral cytopathic effect [28]. These E3 replacements could be used simultaneously to obtain a
multi-therapeutic gene expression with native viral promoters [35].
Later on, in 2005, the same group developed transposon-based approaches to scan an E3-deleted
adenoviral genome for new expression cassette insertion sites. Four different locations were described:
within the E1A promoter, within the E1B gene, between E1A and E1B, and within the E4 untranslated
region (Figure 1) [36]. A similar approach was done with a transgene cassette controlled by different
splice acceptor (SA) variants. They found viable viruses with insertions before 14.7K of E3, between E3
and L5, after L5, and between E4 and ITR (Figure 1). Curiously, most of the inserts were in rightward
orientation (left to right on Ad5 genome) [37]. The level of transgene expression and viral replication
of resulting armed-OAds depended on transgene, promoter, and cassette orientation. Therefore an
optimal insertion site cannot be universally defined.
The impact of transgene orientation had been highlighted previously in gene therapy vectors.
Foreign genes inserted rightwards within E1A, regardless of the promoter, expressed higher levels
than leftward [38]. Transgenes encoded under exogenous promoters in E3 were efficiently transcribed
in both orientations [39]. But others found that DNA inserted rightward in E3 was expressed at higher
levels than leftward orientation [40–42]. In these cases, the inserted gene lacked a strong exogenous
promoter, so the expression was mostly due to transcription initiating upstream to transgene by E3
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promoter or Major Late promoter (MLP). Hence, transgene orientation should be considered at the
time of cloning. In the absence of an exogenous promoter the orientation should coincide with the
replaced adenovirus gene.
Based on the mentioned strategies, most OAds have major deletions within the E3 region. Notably,
E3-deleted viruses were reported to be cleared much more rapidly than wild-type viruses and presented
lower activity in immunocompetent in vivo models [43–45], therefore the E3 deletion may contribute
to the fast clearance of adenoviruses in patients. To circumvent this, different strategies were designed
to insert transgenes in a complete Ad backbone, despite that Ad5 packaging is limited to 38 kb (2 kb
over the wild type size).
For non-E3-deleted OAds the first reported insertion site was right downstream the fiber gene
(fiber is encoded in the late transcription unit 5 -L5-, Figure 1), previously defined also in E3-deleted
backbones [37]. When expressed from the major late promoter as part of the long primary pre-mRNA
transcript, the inserted transgene in this position forms a new transcription unit also known as a Late 6
(L6) unit. A splice acceptor before the transgene start codon allows the formation of the correct mRNA
for the transgene. As a first step to test the feasibility of adding a L6 into Ad5, a GFP [46] or cytosine
deaminase [47] were inserted with splice acceptors. Transgene expression was dependent on viral
replication without any fitness loss. Alternatively, new insertion sites in the late transcription unit 3
(L3) were described cloning the GM-CSF gene between the hexon gene and the 23K protease gene or
downstream the 23K under a splice acceptor (Figure 1). After the hexon significantly affected viral
replication, but downstream the 23K gene showed the highest levels of transgene expression when
compared to E3-19K or E3-14.7K replacements. Linking transgene expression to the L3 transcripts,
which are abundant at the late phase, achieved high levels of transgene expression without affecting
viral growth in a non-deleted adenoviral backbone [48].
3. Genetic Elements that Control Transgene Expression in the Context of Armed OAds
Apart from the insertion site, the transcriptional control of the therapeutic transgene is one of
the main essential features when designing an OAd. With regard to the transcriptional control of the
transgene there have been two main approaches in the field. First, transgenes are inserted as autonomous
expression cassettes containing an exogenous promoter and a polyadenylation signal. In these cases,
the transgene expression does not depend on virus replication. Alternatively, transgenes are inserted
into adenoviral transcription units, taking advantage of the viral gene expression machinery by internal
ribosome entry sites (IRES), splice acceptor sites (SA) or protein fusions using 2A self-cleaving peptide
linkers [49]. This strategy exploits the viral mechanisms of transcription and mimics the timing of
transgene expression within the viral replication cycle and, accordingly, transgenes linked to late phase
genes depend on viral replication. This late-phase selective expression may be used to improve the
safety profile compared with vectors armed with constitutive promoters or early adenoviral promoters.
Alternatively, microRNAs (miRNA) can be used to regulate transgene expression. They are
short-length non-coding RNAs that bind to complementary target sequences, leading to suppression
of gene expression via post-transcriptional regulation. Their use to restrict OAds replication has been
reviewed [50]. Moreover, miRNAs have been used to control transgene expression in Ad vectors [51–53],
and therefore they are an additional strategy to regulate transgene expression in OAds.
3.1. Exogenous Promoters
Exogenous promoters have been extensively used in adenovirus vectors for gene therapy and they
were used in the first armed OAds. The most widely used promoter is the human cytomegalovirus
promoter (CMVp), a constitutive promoter trans-activated by early adenoviral proteins but easily
silenced in mammalian systems. CMVp confers high levels of transgene transcription at early
timepoints independent of virus replication. Transgenes are transcribed in every infected cell, even in
normal tissues. To achieve tumor-selective expression, transgene transcription has been controlled
by cellular promoters overactive in tumor cells. For instance, an OAd encoding GFP controlled by a
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fusion promoter between human telomerase reverse transcriptase (hTERT) and a small fragment of the
CMVp [54]. Progression elevated gene-3 (PEG-3) is selectively expressed in diverse cancer cells, but
it has limited activity in normal tissues. Aiming to control also the timing of transgene expression,
an OAd was armed with a CD-TK fusion gene under heat shock protein 70 (hsp70) promoter. This
promoter allows expression only after induction of 41 °C during 1 h [55]. Nevertheless, hsp70 promoter
efficiently controlled transgene expression by heat-shock induction at early stages of viral infection,
but not after adenovirus genome replication, leading to uncontrolled expression at late stages [56].
The main limitation of exogenous promoters is that they require large DNA fragments, increasing
the size of the transgene cassette, and thus compromising the packaging limit of OAds. Moreover, the
transgene kinetics could not be carefully controlled and becomes independent of virus replication.
3.2. Internal Ribosome Entry Sites (IRES) and 2A Sequences
Internal ribosome entry sites (IRESs) are highly structured viral sequences that facilitate biscistronic
gene expression by internal RNA translation initiation in addition to the cap-dependent translation
at the 5′ of mRNAs. In consequence, IRES allow trangene expression with the same kinetics as
the linked viral gene. When connected to a late gene, transgene expression can be restricted to the
sites of virus replication, which is tumor-selective in the case of OAds. The IRES sequence from the
encephalomyocarditis virus was used to express transgenes from early and late Ad transcription units,
obtaining higher transgene levels than CMV-armed OAds at late stages [47,57–60]. A spacer sequence
between the stop codon and IRES appeared to be crucial for optimal expression [57]. Although IRES
preserve transgene control linked to virus replication; the large size of IRES (aprox. 600 bp) is an obstacle
to insert long trangenes in non-deleted adenoviral backbones. Shorter IRES have been described
(elF4G—339 bp), but they are still far from the size economy of 2A sequences and splice acceptors.
The viral 2A sequences are short peptide sequences that facilitate multiprotein expression from one
open reading frame by a process termed ribosomal skipping [61,62]. Its use in OAds was first described
using the 2A sequences from the foot-and-mouth disease virus F2A and the porcine teschovirus-1
P2A to co-express GFP with adenoviral pIX [63]. Later, transgene selectivity and expression levels
were compared between IRES or thosea asigna virus T2A sequence linked to the fiber gene, or cloned
after E4 by a SA. Higher expression was obtained with IRES or SA than T2A [64]. Most concerning,
2A sequences reduced the replication of the OAds. Thus, other 2A sequences should be tested, or
as an alternative the use of the caspase-8 cleavage site, which has been used between transgenes of
armed-OAds to generate bicistronic transcripts [65,66].
3.3. Splice Acceptors
Alternative splicing was first described for adenovirus late mRNAs [67] and it can be used to
create new transcripts in the adenovirus genome. The short sequence of SA, usually less than 50 bps, is
one of the main advantages for large insertions into the Ad genome.
The IIIa splicing unit and splice enhancer (3VDE) was the first one to be studied in detail [68].
We have used this sequence to express GFP, TK, hyaluronidase, and bispecific T-cell engagers as
transgenes after the fiber, as a L6 unit [46,60,69–71]. Ad40 and Ad41 express two fibers simultaneously
from two SA, thus exploring the SA from these fibers was highly attractive to arm Ad5 with transgenes
after the fiber. The Ad41 long fiber SA was used to introduce the cytosine deaminase gene after Ad5
adenoviral fiber [47]. Alternatively, the SA from Ad40 long-fiber produced at least 50-fold higher
luciferase compared to a CMV-driven cassette at late time points [72]. An artificial splice acceptor site
derived from the beta globulin gene (branch point and splice acceptor sequence (BPSA) has been used
in the adenoviral context to express transgenes [37]. It was also reported the Ad40SA as stronger SA
than BPSA [73]. However, comparisons between these splice acceptors (IIIa, Ad40 SA, Ad41 SA, and
BPSA) in terms of transgene expression levels and viral fitness are not available. In a head to head
study comparing SA and IRES using CD [47] and Luciferase [64], the IRES resulted in the expression of
more transgene but at the expense of selectivity. Thus, the IRES approach might be attractive when the
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insert size and transgene toxicity are not a limitation. Otherwise, SA could be a suitable alternative but
the transgene sequence has to be analyzed for cryptic splice acceptors to prevent undesired or aberrant
transgene products [64].
4. Transgene-Related Parameters that Influence the Outcome of Armed OAds
Several transgene features have to be considered when arming OAds. As mentioned above,
the length of the transgene has a major impact on the design of armed OAds. The insertion of transgenes
longer than 2kb requires deletions in the adenoviral backbone to be adequately packaged into virions.
In these cases, saving genome space to avoid excessive adenoviral gene deletions is crucial, as we have
seen with the detrimental in vivo impact of E3 deletions. Thus, embedding the transgene into deleted
transcription units taking advantage of endogenous promoters or the use of short sequences such as
SA is the best option to control transgene transcription.
The transgene sequence may impact on the arming outcome at different levels. Eukaryotic
transgenes may present introns in their sequences that are important for post-transcriptional stability
and nucleocytoplasmic transport. Indeed, an increase of transgene expression in vitro and in vivo
was reported in gene therapy vectors using introns in the expression cassette [74]. However, as they
increase the transgene length, introns have not been used in OAds.
The set of codons encoding the transgene, known as the codon usage, might also affect its
expression and viral fitness. We reported that adenovirus proteins could be grouped according to
their codon usage. In particular, most early viral regulatory proteins used codons with A/T ending,
while proteins implicated in replication and virion formation, including structural proteins, used
codons ended in G/C. However, the fiber presented a different codon usage compared to the rest of
the structural proteins, which was also poorly adapted to the human codon usage. Optimization of
the Ad5 fiber gene sequence to the human codon usage in an adenovirus decreased fiber expression
and reduced expression of other structural proteins such as hexon and penton, compromising viral
fitness. Furthermore, the introduction of GFP as a late gene after fiber under a splicing acceptor further
reduced viral fitness [75].
According to these results, changing a given protein codon usage, such as the fiber, could
generate an imbalance in aminoacylated-tRNA (aa-tRNA) use between structural proteins resulting in
a competition for the same aa-tRNA host pool leading to decreased late protein expression and viral
fitness. This could explain why the insertion of a transgene as a late gene, in this case GFP, with a codon
usage competing with structural proteins further attenuated virus replication. The results suggest that
transgene codon usage should be adapted to avoid competing with the aa-tRNA frequently used by
late genes, a feature to consider when arming OAds.
The level of transgene needed for the therapeutic effect or the potential cytotoxicity of the transgene
should be taken into account for the selection of the appropriate transgene location or transcriptional
control elements. For instance, non-cytotoxic transgenes could be encoded in early regions with
constitutive promoters or linked to adenoviral late genes. Otherwise, cytotoxic transgenes that may
hamper virus-producer cells before completing the viral replication cycle should be encoded in late
phases and at lower amounts to allow proper virus replication. The constitutive or immediately early
phase expression does not restrict the transgene transcription to the tumor and all infected cells produce
transgene, independently of virus replication. Regarding this, toxicity in vivo has to be addressed,
especially in systemic administrations.
Therefore, transgene function is a key feature for arming design. The function of transgenes can
be considered virocentric or immunocentric. Virocentric transgenes would enhance virus cytotoxicity,
yields or spread. Immunocentric transgenes aim to enhance the immune responses elicited during
the oncolysis. The rationale behind immunocentric arming is that anti-tumor immune response may
be the ultimate mechanism of efficacy for OAds. Here, we review some examples of both types of
transgenes and summarize the armed-OAds in clinics.
Cancers 2020, 12, 1034 7 of 18
4.1. Virocentric Transgenes
Transgenes aiming to improve the oncolytic effect, enhance virus spread, or kill bystander
non-infected cells can be considered virocentric. Initially, genes used to arm OAds were
prodrug-converting enzymes for molecular chemotherapy, known as suicide genes. These enzymes
promote the conversion of intravenously administered non-toxic prodrugs to toxic drugs in
adenovirus-infected cells, resulting in high local concentrations in the tumor. They induce a bystander
effect of the toxic drug with limited systemic toxicity. Some examples of commonly used enzymes are
herpes simplex virus thymidine kinase (TK) [25], bacterial or yeast-derived cytosine deaminase (CD or
yCD) [47,76], bacterial nitroreductase (NTR) [59,77,78], carboxylesterase [79], and carboxypeptidase
G2 (CPG2) [80]. Fusion of these proteins, CD-TK [23,24], or improved versions of them were used to
arm OAds [60,81]. As suicide genes are non-toxic by themselves and the bystander effect depends on
prodrug administration, these armed-OAds could encode the transgene in early or late phase with
constitutive promoters or other strategies. Linking their expression to late phase genes may lead to
higher amounts of transgene.
Following this rationale, toxins were also used to kill surrounding non-infected cells. For instance,
an OAd was armed with melittin, a water-soluble toxic peptide from the bee venom that induces cell
apoptosis [82,83]. Toxins fused to antibodies’ single-chains (ScFv), called immunotoxins, were used
to target specific cells. An OAd harboring a secreted anti-EGFR-scFv fused to the RNase onconase
produced a potent EGFR-dependent bystander killing of tumor cells in vitro and enhanced tumor cell
death in vivo [73]. As toxins may have detrimental effects in the virus-producer cell, even with low
concentrations, early expression should be avoided to ensure efficient viral replication. For example,
linking onconase transcription to late phase with a weak SA was the only arming design leading to
viable virus.
Another virocentric approach is to enhance the viral release and spread of OAds. Apoptosis
stimulates adenoviral spread through apoptotic bodies [84]. When apoptosis is induced at a late stage
of the virus cycle, it does not affect the production of viruses and increases their release from the cell.
In consequence, any apoptosis-inducing transgene should be expressed at late phases of the viral
cycle. One of the cell death pathways exploited by adenoviruses involves p53. Many cancer cells
have non-functional p53 and consequently do no support OAd-induced cell death. Therefore, OAds
armed with p53 showed enhanced viral release at the late phase [58,85]. Similarly, other apoptosis
inducers have been used to arm OAds such as TNFα [26–28,86] or TNF-related apoptosis-inducing
ligand (TRAIL). Soluble TRAIL derivatives induce apoptosis independent of p53 status and thus may
benefit OAd release in a broad range of tumors. For this reason, sTRAIL has been extensively used in
OAds [66,87–91]. Different transgenes that induce late apoptosis have been reported [66,92–95].
Another strategy to increase the cytotoxicity of OAds is based on RNA interference (RNAi), recently
reviewed [50]. Briefly, miRNAs and shRNAs have been inserted to enhance viral replication [96].
In this line, we have recently shown that miR-99b and miR-485 act as enhancers of adenoviral oncolysis
by regulating viral transcriptional repressors [97]. Moreover, OAds armed with RNAs (miRNA,
shRNA, lncRNA) have been described to silence oncogenes, pro-angiogenic growth factors or apoptosis
inhibitors to promote cell death [88,98–104]. A clear advantage of using RNAs is the absence of
packaging limitations, as they tend to be short. However, as with transgenes, their temporal expression
must be selected according to its function.
Connective tissue, fibrosis, and extracellular matrix hamper viral spread in the tumor [105]. OAds
have been armed to digest the connective tissue. An armed-OAd encoding for relaxin, a peptide
hormone able to induce remodeling by degrading collagen and up-regulating matrix metalloproteases,
improved the oncolytic potential and tumor spreading in highly metastatic tumor models [106,107].
VCN-01 (Table 1) is an oncolytic adenovirus armed with a soluble version of human hyaluronidase
(PH20; SPAM1) to degrade hyaluronic acid from the tumor matrix [69,108–111]. VCN-01 is currently
in clinical trials in pancreatic, retinoblastoma, and head and neck cancers. Hyaluronidase has been
used also in a chimeric serotype 11/3 OAd. In this backbone, the DNAse I degraded the extracellular
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DNA, which was also identified as a barrier for interstitial virus spread [112]. Matrix remodeling
transgenes don’t affect cell viability allowing early phase expression, but potential toxicity in vivo may
still require late and tutor-selective expression.
Table 1. Armed oncolytic adenoviruses in clinical trials.




∆E3 E1b55K, E3 CMV yCD/TK, hIL-12
NCT02555397
NCT03281382




CG0070 Ad5 E1a ∆24E3∆19K
Between 6.7
and ADP End. P GM-CSF NCT02143804
ONCOS-102 Ad5; Ad3fiber knob
E1a∆24



















NG-350A Ad11/3 NA NA NA CD40 agonistmAb NCT03852511
Ins.Site: Insertion Site; CMV: Cytomegalovirus; GM-CSF: Granulocyte Macrophage Colony Stimulating Factor
End.P: Endogenous Promoter, FAP-BiTE: Fibroblast Activation Protein - Bispecific Tcell Engager; NA: Information
not available.
Fusogenic membrane glycoproteins induce cell-cell fusion and massive syncytia formation.
OAds have been armed with measles virus fusogenic membrane glycoprXoteins [113] or gibbon-ape
leukemia virus (GALV) envelope glycoprotein [114] significantly enhancing the antitumor efficacy. Also,
the formation and subsequent disintegration of the induced syncytia are highly immunostimulatory
and have the potential to produce strong systemic bystander effects [115,116]. As adenovirus egress
poorly from syncytia, and late phase expression of fusogenic proteins should be considered.
4.2. Immunocentric Transgenes
In the last decade, mounting evidence that the immune system can be a powerful ally to cure
cancer, mostly fostered by the development of checkpoint inhibitors in oncology, has shifted the
strategy in favor of immunocentrism. Oncolytic viruses are an excellent adjuvant for immunotherapy
by debulking the tumor, releasing tumor antigens, and providing the appropriate danger signals to
inflame tumors and make them susceptible to immunotherapy treatments. As a clear example of
this trend, arming OAds with immune-stimulatory cytokines or redirecting immune molecules has
emerged as the main approach to prevent cancer spread and recurrence by overcoming the immune
tolerance in the tumor. OAds with these transgenes usually contain E3 deletions to provide space and
eliminate E3 immune evading functions, and the transgene is expressed early or constitutively. This
approach has been widely used, and it is suitable for the most of cases. However, if used systemically
such a constitutive expression could lead to toxicity, and it might be appropriate to consider late phase
tumor-selective expression.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the development,
recruitment, activation, and survival of dendritic cells, which are vital for antitumor immunity.
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ONCOS-102 (Table 1) is an oncolytic virus-based in the Ad5 genome with Ad3 fiber knob and GM-CSF
replacing adenoviral E3A. Safety and immunological activity of ONCOS-102 have already been
demonstrated in a phase I clinical study for refractory tumors [117–119]. CG0070 (Table 1) is also an
E3-deleted GM-CSF armed-OAd that in a phase I clinical trial in nonmuscle invasive bladder cancer
has shown minor toxicity, viral replication, and high levels of GM-CSF in urine in all patients [120,121].
Interleukin 12 (IL-12) is a heterodimeric cytokine that strongly promotes T-cell helper type 1
(Th1) responses by activating macrophages and dendritic cells. OAds with IL-12 alone or combined
with other immune molecules showed antitumor activity even in murine models where human
adenoviruses are not able to replicate [122–124]. Ad5-yCD/mutKSR39rep-hIL12 (Table 1) is an oncolytic
adenovirus combining IL-12 and yeast cytosine deaminase (yCD) which is in a Phase-I clinical trial in
pancreatic cancer (NCT03281382). OAds have also been armed with: IL-15 [125,126], IL-21 [127], or
IL-24 [128–133].
The combination of immunostimulatory cytokines and immune ligands represent the latest trend.
Arming with TNFα and IL-2 caused a Th1 enhanced immune response in preclinical models [134]
and the OAd TILT-123 advanced to the clinics in melanoma patients receiving an anti-PD1 therapy
(Table 1). The LOAd703 (Table 1) is an adenovirus derived from serotype 5 with the fiber from serotype
35, and partial deletion in E3 to express the transgenes trimerized membrane-bound isoleucine zipper
(TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter [135]. It is being
tested in clinics as a monotherapy in a variety of cancers or in combination with immunotherapy in
malignant melanoma.
Despite the unprecedented efficacy of immune checkpoint inhibitors (ICIs) for certain tumor
types, lack of responses in many poorly inflamed (cold) tumors and the systemic autoimmune toxicity
have prompted the use of OAds to deliver ICIs. An OAd producing a full-length human monoclonal
antibody specific for CTLA4 was published for first time in 2012 [136]. Later, anti-HER2 monoclonal
antibody has also been published [137]. NG-350A (Table 1) is an oncolytic adenovirus based on
serotypes 11/3 which encodes for a complete anti-CD40. It is currently being tested in clinical trials for
metastatic or advanced epithelial tumors administered intratumorally or intravenously.
Armed-OAds evolve in parallel to the immunotherapy landscape. OAds have been designed to
produce soluble ligands of immune checkpoints such as OX40L [138], GITRL [139] or a fusion protein
sPD1-CD137L [140], and also targeting crucial molecules for the resistance to anti-PD1/PD-L1 and
anti-CTL-4 therapies such as TGF-β [141,142]. Moreover, the generation of bispecific T-cell engagers
(BiTE) opened a new opportunity for redirecting the anti-viral lymphocytes against tumor-specific
antigen. An OAd armed with an EGFR-targeting BiTE showed promising results alone [70] or in
combination with CAR-T cell therapy [143]. OAds expressing BiTEs against Epcam [144] or FAP [71]
antigens were also reported. NG-641 (Table 1) currently in a clinical trial is armed with 4 transgenes:
Interferon alpha (IFNα) to drive dendritic cell priming, CXCL9 and CXCL10 to recruit T-cells and
FAP-BiTE to redirect them.
5. Conclusions
The best arming strategy depends on the transgene and the desired amount and timing of
expression. We have reviewed all published genome insertions sites in oncolytic adenoviruses.
Most armed OAds have E3 deletions, which reduces the virus persistence in vivo due to a lower
immune-evasion. Thus, we postulated that E3 insertion site could be beneficial for immunocentric
transgenes aiming to stimulate the immune system. On the other hand, we suggest that virocentric
transgenes or those that need higher expression could be inserted at late sites in non-E3 deleted
viruses for longer persistence in vivo, always considering the packaging limits of the virus. In terms of
transcriptional control, taking advantage of the endogenous E3 promoters using gene replacements
or the major late promoter using splice acceptors allows efficient expression with minimal genomic
size increase. In particular the use of the major late promoter allows high expression linked to the
virus replication.
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